Suppr超能文献

基于免疫组织化学分析的 Ep-ICD 亚细胞定位指数(ESLI)是转移性甲状腺微小乳头状癌的一种新的标志物。

Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma.

机构信息

Alex and Simona Shnaider Laboratory in Molecular Oncology, Department of Pathology & Laboratory Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 60 Murray Street, Suite L6-304, Toronto, ON, M5T 3L9, Canada.

出版信息

BMC Cancer. 2012 Nov 15;12:523. doi: 10.1186/1471-2407-12-523.

Abstract

BACKGROUND

Thyroid cancer is among the fastest growing malignancies; almost fifty-percent of these rapidly increasing incidence tumors are less than or equal to 1cm in size, termed papillary thyroid microcarcinoma (PTMC). The management of PTMC remains a controversy due to differing natural history of these patients. Epithelial cell adhesion molecule (EpCAM) is comprised of an extracellular domain (EpEx), a single transmembrane domain and an intracellular domain (Ep-ICD). Our group reported nuclear Ep-ICD correlated with poor prognosis in thyroid cancer (Ralhan et al., BMC Cancer 2010,10:331). Here in, we hypothesized nuclear and cytoplasmic accumulation of Ep-ICD and loss of membranous EpEx may aid in distinguishing metastatic from non-metastatic PTMC, which is an important current clinical challenge. To test our hypothesis, Ep-ICD and EpEx expression levels were analyzed in PTMC and the staining was correlated with metastatic potential of these carcinomas.

METHODS

Thirty-six PTMC patients (tumor size 0.5 - 1cm; metastatic 8 cases and non-metastatic 28 cases) who underwent total thyroidectomy were selected. The metastatic group consisted of patients who developed lymph node or distant metastasis at diagnosis or during follow up. The patients' tissues were stained for Ep-ICD and EpEx using domain specific antibodies by immunohistochemistry and evaluated.

RESULTS

PTMC patients with metastasis had higher scores for nuclear and cytoplasmic Ep-ICD immunostaining than the patients without metastasis (1.96 ± 0.86 vs. 1.22 ± 0.45; p = 0.007 and 5.37 ± 0.33 vs. 4.72 ± 1.07; p = 0.016, respectively). Concomitantly, the former had lower scores for membrane EpEx than the non-metastatic group (4.64 ± 1.08 vs. 5.64 ± 1.51; p = 0.026). An index of aggressiveness, Ep-ICD subcellular localization index (ESLI), was defined as sum of the IHC scores for accumulation of nuclear and cytoplasmic Ep-ICD and loss of membranous EpEx; ESLI = [Ep - ICDnuc + Ep - ICDcyt + loss of membranous EpEx]. Notably, ESLI correlated significantly with lymph node metastasis in PTMC (p = 0.008).

CONCLUSION

Nuclear and cytoplasmic Ep-ICD expression and loss of membranous EpEx were found to correlate positively with metastasis in PTMC patients. In addition, ESLI had the potential to identify metastatic behavior in PTMC which could serve as a valuable tool for solving a current dilemma in clinical practice.

摘要

背景

甲状腺癌是增长最快的恶性肿瘤之一;这些快速增长的肿瘤中,近 50%的肿瘤直径小于或等于 1cm,称为甲状腺微小乳头状癌(PTMC)。由于这些患者的自然病史不同,PTMC 的治疗管理仍然存在争议。上皮细胞黏附分子(EpCAM)由细胞外结构域(EpEx)、单一跨膜结构域和细胞内结构域(Ep-ICD)组成。我们的研究小组报告称,甲状腺癌中核内 Ep-ICD 与预后不良相关(Ralhan 等人,BMC Cancer 2010,10:331)。在这里,我们假设 Ep-ICD 的核内和细胞质积聚以及膜 EpEx 的丢失可能有助于区分转移性和非转移性 PTMC,这是当前临床面临的重要挑战。为了验证我们的假设,我们分析了 PTMC 中的 Ep-ICD 和 EpEx 表达水平,并将染色与这些癌的转移潜能相关联。

方法

选择了 36 名接受甲状腺全切除术的 PTMC 患者(肿瘤大小为 0.5-1cm;转移 8 例,非转移 28 例)。转移组包括在诊断或随访期间发生淋巴结或远处转移的患者。使用针对特定结构域的抗体通过免疫组织化学对患者组织中的 Ep-ICD 和 EpEx 进行染色并进行评估。

结果

与无转移的患者相比,发生转移的 PTMC 患者的核内和细胞质 Ep-ICD 免疫染色评分更高(1.96±0.86 与 1.22±0.45;p=0.007 和 5.37±0.33 与 4.72±1.07;p=0.016,分别)。同时,前者的膜 EpEx 评分低于非转移性组(4.64±1.08 与 5.64±1.51;p=0.026)。一个侵袭性指标,Ep-ICD 亚细胞定位指数(ESLI),定义为核内和细胞质 Ep-ICD 积聚和膜 EpEx 丢失的 IHC 评分之和;ESLI=[Ep-ICDnuc+Ep-ICDcyt+loss of membranous EpEx]。值得注意的是,ESLI 与 PTMC 中的淋巴结转移显著相关(p=0.008)。

结论

在 PTMC 患者中,核内和细胞质 Ep-ICD 表达和膜 EpEx 的丢失与转移呈正相关。此外,ESLI 有可能识别 PTMC 的转移行为,这可能成为解决当前临床困境的有用工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验